Hormone-receptor-negative breast cancer—most of it triple-negative, meaning the tumor lacks estrogen receptors, progesterone receptors and surplus HER2—is among the most lethal common subtypes of the disease. It disproportionately strikes younger women and carriers of BRCA1 mutations, grows quickly, and metastasizes early. Once it reaches distant organs, survival is measured in a few years at best, and historically it was counted in months. Recent gains have been incremental at best. Platinum salts and taxanes remain the chemotherapy backbone, and pembrolizumab added to chemotherapy extends life chiefly in the minority of patients whose tumors express the PD-L1 protein at high levels—a biomarker found in fewer than half of metastatic cases. For everyone else, checkpoint inhibitors have offered little. Adding to the challenge, pathologists now recognize that a large share of these apparently HER2-negative tumors are not truly negative: they carry low levels of the HER2 protein on the cell surface, visible as faint immunohistochemical staining, a state the field has termed HER2-low.

HER2-low is defined as cancer scored 1+ on immunohistochemistry, or 2+ with no gene amplification on in situ hybridization—receptor levels once dismissed as biologically irrelevant. Trastuzumab deruxtecan, developed by Daiichi Sankyo and AstraZeneca, changed that view. The drug consists of a trastuzumab antibody tethered through an enzyme-cleavable tetrapeptide linker to deruxtecan, a potent inhibitor of topoisomerase I, an enzyme that dividing cells need to untangle DNA during replication. With roughly eight payload molecules riding on each antibody—a drug-to-antibody ratio far higher than earlier conjugates achieved—the drug delivers a concentrated chemotherapy dose directly to HER2-expressing cells. After the antibody binds its target and is engulfed into the lysosome, tumor-cell enzymes clip the linker, releasing the payload to poison DNA replication. Critically, the released drug is membrane-permeable, so it diffuses into neighboring tumor cells that express little or no HER2. This bystander effect explains why the conjugate works at receptor densities once considered far too low to target, and in earlier randomized studies it roughly doubled progression-free survival compared with standard chemotherapy in pretreated patients with HER2-low metastatic disease.

Durvalumab attacks the tumor from a different direction. The monoclonal antibody binds PD-L1, the molecular brake that tumors and immune cells deploy to shut down cytotoxic T lymphocytes, releasing those cells to resume their attack. The logic for combining it with trastuzumab deruxtecan rests on a decade of tumor immunology showing that antibody-drug conjugates do far more than kill their targets. The DNA damage inflicted by topoisomerase I inhibition can activate the cGAS–STING pathway, the cell’s alarm sensor for misplaced DNA, triggering type I interferon release. Dying tumor cells spill antigens that dendritic cells carry to lymph nodes for T-cell priming, while stressed tumor cells raise the density of MHC class I molecules and PD-L1 on their surface. In laboratory models, topoisomerase I inhibitors effectively behave as an in situ vaccine, converting immunologically cold tumors into inflamed ones that checkpoint inhibitors can exploit. The question BEGONIA posed was whether this mechanistic synergy would hold in human breast cancer, in women receiving both agents as their first treatment for advanced disease.

BEGONIA was conceived as a platform study rather than a single comparison: multiple parallel arms tested durvalumab alongside different investigational partners, including antibodies against CD73 and NKG2A, a STAT3-targeting antisense oligonucleotide, and trastuzumab deruxtecan. The design allowed several drug combinations to be evaluated simultaneously under shared infrastructure, with each arm reporting once it accrued enough patients. The arm reported in Nature Cancer enrolled women with locally advanced, unresectable or metastatic hormone-receptor-negative breast cancer whose tumors were HER2-low and who had not yet received drug therapy for advanced disease. Patients received both agents at established doses on three-week cycles, continuing until their disease progressed or toxicity became unacceptable. Because the study was open-label and lacked a randomized control group, its primary endpoint was the objective response rate—the proportion of patients whose tumors shrank by at least 30 percent, as confirmed by blinded independent central review—together with duration of response, progression-free survival and safety. Enrollment spanned cancer centers across Europe, Asia and North America, capturing the heterogeneity of real-world clinical populations.

The efficacy signals exceeded what either drug’s record alone would predict. Around 62 percent of patients achieved a confirmed objective response, and a small subset saw all detectable disease disappear—complete responses that are rare with conventional first-line chemotherapy in this setting. The median duration of response had not been reached when the data were locked, with the majority of responses still ongoing at analysis and many patients remaining on treatment beyond a year. Notably, responses appeared across the cohort irrespective of tumor PD-L1 expression, hinting that the combination might reach patients who historically derive little benefit from checkpoint inhibition. Disease control—tumors that shrank or remained stable—encompassed the large majority of treated patients. Whether that translates into longer survival will require longer follow-up, but the depth and persistence of the early responses is precisely what caught researchers’ attention in a disease where first-line chemotherapy shrinks tumors in only about a third of cases.

The safety profile combined the known liabilities of both drugs. Toxicities consistent with trastuzumab deruxtecan—nausea, fatigue, hair loss and myelosuppression, particularly anemia and neutropenia—were common, and roughly half of patients experienced grade 3 or worse treatment-related events that required dose interruption or reduction. Durvalumab contributed immune-mediated effects such as thyroid dysfunction and liver enzyme elevations. The toxicity demanding the most vigilance was interstitial lung disease, the inflammatory lung injury recognized as a class effect of trastuzumab deruxtecan across its development program. It occurred in only a small fraction of patients, predominantly at low grade, and was managed with treatment interruption and corticosteroids. No unexpected safety signals emerged, the investigators report, and the pattern of events matched what had been seen when each drug was used alone. Yet because durvalumab can itself provoke pneumonitis, the overlap of two lung-toxicity risks made pulmonary monitoring a central element of the protocol, with clinicians urged to suspect drug-related lung injury in any new respiratory symptom and to treat it early.

The trial was led by Peter Schmid of Queen Mary University of London, with Se Hyun Im of Asan Medical Center in Seoul and Zbigniew Nowecki of the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw among the senior investigators. Writing in Nature Cancer, the authors describe response rates that compare favorably with historical benchmarks for first-line therapy in hormone-receptor-negative, HER2-low disease, and argue that the pairing’s activity independent of PD-L1 status addresses one of immunotherapy’s persistent blind spots in this subtype. They are careful, however, to frame the study as hypothesis-generating. With a single-arm design and no randomized comparator, the results establish feasibility, response depth and tolerability, but not survival advantage. The authors call for the regimen to be advanced into randomized phase III testing, where durvalumab plus trastuzumab deruxtecan would be measured head-to-head against the current standards of pembrolizumab with chemotherapy and chemotherapy alone.

The results arrive at a moment when the logic of breast cancer sequencing is being rewritten. Trastuzumab deruxtecan is already approved for HER2-low metastatic disease, but only after patients have progressed on earlier lines of therapy; its position has been in the back half of the treatment journey. Moving the drug to the front line, and pairing it with an immunotherapy, raises immediate questions. Do patients who receive the conjugate early forfeit its later benefit if the disease eventually progresses, or does earlier exposure translate into longer survival? How should clinicians handle tumors that are HER2-ultralow, expressing the protein at even fainter levels that current tests barely register? And does the HER2-low label, which depends on subjective immunohistochemistry scoring, reliably identify the right patients when the stakes are a front-line regimen? The HER2-low population is also biologically heterogeneous, mixing immunologically inflamed tumors with cold ones, and translational analyses from BEGONIA are expected to clarify which microenvironments the combination actually reprograms.

For now, the findings stand as a proof of principle: a targeted chemotherapy payload and an immune checkpoint inhibitor can be combined safely and effectively as an initial treatment in one of breast cancer’s most difficult molecular neighborhoods. If randomized trials confirm the kind of survival gains that single-arm data cannot demonstrate, the first-line landscape for hormone-receptor-negative, HER2-low metastatic disease could shift away from cytotoxic chemotherapy toward regimens that couple precision targeting with immune activation—a strategy oncologists have pursued across solid tumors for a decade. The necessary next step—randomized confirmation—will determine whether regulators follow where the biology points. With survival in this population still measured in only a few years, and breast cancer remaining the leading cause of cancer death in women worldwide, the stakes are considerable. The BEGONIA results suggest the tools to change that arithmetic may already be in hand; what remains is to prove, in the rigorous language of randomized evidence, that the promise holds.